Skip to main navigation
Skip to search
Skip to main content
Sort by
Biochemistry, Genetics and Molecular Biology
Cancer Cell
58%
Genome Instability
53%
Gene Expression Profiling
44%
RNA-binding Protein
41%
Carcinogenesis
34%
Lamin
33%
Neuroendocrine Cell
33%
R-Loop
33%
Drive
33%
Transcriptomics
33%
Genomics
33%
Transcription
28%
Topoisomerase
28%
DNA Topoisomerase
28%
Gene Expression
27%
Gene Amplification
25%
ELAVL1
24%
RNA
22%
NEUROD1
22%
Blood Plasma
22%
Exome
22%
Clinical Trial
19%
Oncogene
19%
Targeted Therapy
19%
Tumor Progression
18%
Deficiency
18%
Gene Mutation
18%
DNA Damage Response
16%
Proteolysis
16%
Glycoside Hydrolase
16%
Ataxia Telangiectasia and Rad3 Related
16%
ASCL1
16%
Modifier Gene
16%
Cell Cycle
16%
Immune Checkpoint Inhibitor
16%
PD-L1
16%
Gene Signature
16%
Kinase
16%
Phosphotransferase
16%
Transcriptome
16%
Synapsin I
16%
Reprogramming
16%
Ubiquitin
16%
YAP1
16%
Adenosine Diphosphate Ribose
16%
RNA Polymerase II
16%
Chromatin
16%
Upregulation
16%
Anticancer
13%
Genetics
12%
Medicine and Dentistry
Pancreas Cancer
100%
Pancreas Adenocarcinoma
87%
Small Cell Lung Cancer
49%
Overall Survival
45%
Neoplasm
39%
Progression Free Survival
38%
Berzosertib
33%
Pancreaticoduodenectomy
33%
Malignant Neoplasm
29%
Tumor
28%
Intraductal Papillary Mucinous Tumor
25%
Vascularity
25%
Chemotherapy
24%
Genetics
22%
Clinical Trial
19%
Topotecan
16%
Cancer Cell
16%
Metastatic Carcinoma
16%
Glycosidase
16%
Neck
16%
Pyrvinium
16%
Echo Contrast Medium
16%
Bile Duct
16%
Sacituzumab Govitecan
16%
Respiratory Disease
16%
Drug Resistance
16%
Hypercapnia
16%
Alveolar Type II Cells
16%
Immunofluorescence
16%
Mitochondrion
16%
Randomized Clinical Trials
16%
Joint Committee
16%
Cellular Senescence
16%
Poly(adenosine Diphosphate Ribose)
16%
Idiopathic Pulmonary Fibrosis
16%
Metastatic Organotropism
16%
Cell-Free DNA
16%
Hazard Ratio
13%
Adenocarcinoma
13%
Diseases
13%
DNA Damage Response
11%
Multivariate Analysis
11%
Univariate Analysis
11%
Proportional Hazards Model
10%
Xenograft
10%
Tumor Biopsy
9%
Antibody-Drug Conjugate
8%
Lung
8%
Identified Patient
8%
Organ Donor
8%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Adenocarcinoma
93%
Pancreas Cancer
83%
Small Cell Lung Cancer
50%
Pyrvinium Embonate
50%
Malignant Neoplasm
40%
Anthelmintic Agent
35%
Clinical Trial
27%
Neoplasm
26%
Berzosertib
25%
Anticarcinogen
22%
Topotecan
20%
Repurposing
19%
Diseases
16%
RNA Binding Protein
16%
Poly(adenosine Diphosphate Ribose)
16%
Echo Contrast Medium
16%
Sonoporation
16%
Randomized Clinical Trial
16%
Sacituzumab Govitecan
16%
Lurbinectedin
16%
Abemaciclib
16%
Nanocarrier
16%
Pancreas Tumor
16%
Glycosidase
16%
Synapsin I
16%
Chemotherapy Regimen
12%
Gemcitabine
8%
Overall Survival
8%
Perflubutane
8%
Perflutren
8%
Progression Free Survival
8%
Messenger RNA
8%
Carcinogenesis
6%
Luciferase
6%
Folic Acid
6%
Sulfur Hexafluoride
5%
Cyclin D1
5%
